Robustness to pleiotropy
The argument
Because linked claim, and because instruments in distinct LDL genes converge on the same per-unit effect, a pattern gene-specific pleiotropy would not produce, and because LDL retains an independent effect in multivariable MR that conditions on HDL and triglycerides, so the shared-lipid pleiotropy that is known to exist does not carry the causal signal, and because the genetic estimates agree with randomized LDL-lowering trials, the genetic instruments appear to act on cardiovascular risk through LDL rather than through side pathways.
Does it work?
Not yet evaluated.
Premises
- SupportedThe evidence favors the claim, but the examination is incomplete or the evidence is indirect.constitution →MR sensitivity analyses find no evidence of directional pleiotropy in the genetic LDL–cardiovascular disease relationship
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Genetic instruments in distinct LDL-related genes yield concordant estimates of LDL's effect on cardiovascular risk
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Mendelian randomization and statin-trial estimates of LDL's cardiovascular effect are mutually consistent once duration of exposure is accounted for
- VerifiedThe evidence, examined directly, establishes the claim.constitution →Multivariable Mendelian randomization adjusting for HDL and triglycerides shows LDL retains an independent causal effect on cardiovascular risk
Where it is made
Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.
No source is recorded as making it.
Earlier ratings
- Jul 19, 2026
The inference goes through: if instruments in distinct genes converge on the same per-unit effect, that effect survives conditioning on the other lipids, sensitivity analyses show no directional pleiotropy, and the genetic estimates match randomized-trial effects, the instruments plausibly act through LDL rather than side pathways. It rests most heavily on the concordance of per-unit estimates across distinct LDL genes and on LDL's independent effect surviving multivariable adjustment for HDL and triglycerides, both verified. The trial-agreement leg, agreement with randomized LDL-lowering trials once exposure duration is accounted for, now stands as verified rather than merely consistent, so it reinforces the inference more firmly than before, alongside the absence of directional pleiotropy in sensitivity analyses. The apoB refinement bears on which lipid measure is proximally causal rather than reintroducing non-lipid pleiotropy, so it does not weaken the inference.
- Jul 19, 2026
The inference goes through: if instruments in distinct genes converge on the same per-unit effect, that effect survives conditioning on the other lipids, sensitivity analyses show no directional pleiotropy, and the genetic estimates match randomized-trial effects, the instruments plausibly act through LDL rather than side pathways. It rests most heavily on the concordance of per-unit estimates across distinct LDL genes and now more firmly on LDL's independent effect surviving multivariable adjustment for HDL and triglycerides, which has moved from unassessed to verified and directly answers the confirmed lipid-trait pleiotropy. It is further supported by the absence of directional pleiotropy in sensitivity analyses and by agreement with randomized trials. The apoB refinement refines which lipid measure is causal rather than reintroducing non-lipid pleiotropy, so it does not weaken the inference.
- Jul 19, 2026
The inference goes through: if instruments in distinct genes converge on the same per-unit effect, that effect survives conditioning on the other lipids, sensitivity analyses show no directional pleiotropy, and the genetic estimates match randomized-trial effects, the instruments plausibly act through LDL rather than side pathways. It rests most heavily on the concordance of per-unit estimates across distinct LDL genes, the pattern gene-specific pleiotropy would fail to produce, and on LDL's independent effect surviving multivariable adjustment for HDL and triglycerides, the correction aimed at the confirmed lipid-trait pleiotropy. It is further supported by the absence of directional pleiotropy in sensitivity analyses and now by agreement with randomized trials, whose roughly threefold per-unit gap is explained by lifelong versus short-term exposure and so reinforces rather than undermines the inference.
- Jul 19, 2026
The inference goes through: if instruments in mechanistically distinct genes converge on the same per-unit effect, that effect survives conditioning on the other lipids, sensitivity analyses show no directional pleiotropy, and the genetic estimates match randomized-trial effects, the instruments plausibly act on cardiovascular risk through LDL rather than side pathways. It rests most heavily on the concordance of per-unit estimates across distinct LDL genes, which is verified and is the pattern gene-specific pleiotropy would fail to produce. Now that lipid-trait pleiotropy is confirmed real, the argument leans additionally on LDL's independent effect surviving multivariable adjustment for HDL and triglycerides, the correction aimed squarely at that pleiotropy; it is further supported by the absence of directional pleiotropy in sensitivity analyses, while agreement with randomized trials remains consistent though not yet formally assessed.
- Jul 19, 2026
The inference goes through: if instruments in mechanistically distinct genes converge on the same per-unit effect, sensitivity analyses show no directional pleiotropy, and genetic estimates match randomized-trial effects, the instruments plausibly act on cardiovascular risk through LDL rather than side pathways. The argument now rests most heavily on the concordance of per-unit estimates across distinct LDL genes, which has been independently verified and is the pattern gene-specific pleiotropy would fail to produce. It is further supported by the absence of directional pleiotropy in MR sensitivity analyses, while agreement with randomized LDL-lowering trials remains consistent though not yet formally assessed.
- Jul 19, 2026
The inference goes through: three independent signatures point the same way, and confounding pleiotropy would be expected to disturb at least one. The argument's weight rests mainly on the concordance of estimates across distinct LDL genes (verified) and agreement with randomized LDL-lowering trials, since these directly exclude a shared confounding pathway; the null directional-pleiotropy tests add support but carry less weight on their own because such tests have limited power.